Latent membrane protein 1, the EBV-encoded oncogenic mimic of CD40, accelerates autoimmunity in B6.Sle1 mice.
EBV infection is associated with development of the autoimmune disease systemic lupus erythematosus (SLE), and EBV can reactivate during SLE flares. Latent membrane protein 1 (LMP1) is an EBV-encoded oncogenic mimic of CD40 that can be re-expressed in PBMCs during SLE flares, as >90% of humans are latently EBV-infected. Whether LMP1 signaling exacerbates SLE is unknown. The phenotype of mice expressing a chimeric molecule with the mouse CD40 extracellular domain and the LMP1 intracellular signaling regions (mCD40-LMP1 transgenic [tg]) includes enhanced autoreactivity, yet these mice do not develop fatal autoimmune disease. We hypothesized that LMP1-mediated activation signals cooperate with and/or amplify events that predispose individuals to development of autoimmunity. To determine which aspects of autoimmunity may be exacerbated by LMP1, we bred mCD40-LMP1tg mice to two lupus-prone strains, B6.Sle1 and B6.Sle3, and analyzed autoimmunity parameters. LMP1(+)Sle1(+/+) mice developed enlarged lymphoid organs containing increased frequencies of germinal center, B cells, CD86(+) B cells, and activated and memory T cells compared with non-tg littermates. Anti-histone Abs were elevated in serum of LMP1(+)Sle1(+/+) mice, and they had signs of kidney pathology. LMP1(+)Sle1(+/+) B cells produced increased IL-6 and upregulated CD86 to a higher degree following CD40 stimulation in vitro, suggesting that the in vivo autoimmune exacerbation is B cell intrinsic. In contrast, the LMP1 transgene has no additional effects on autoimmunity on the B6.Sle3 background. These data indicate that LMP1-induced effects can cooperate with distinct subsets of host genes that predispose to autoimmunity and can thus be an exacerbating factor in autoimmune disease via multiple mechanisms.
Peters
Anna L
AL
Immunology Graduate Program, University of Iowa, Iowa City, IA 52242, USA.
Stunz
Laura L
LL
Meyerholz
David K
DK
Mohan
Chandra
C
Bishop
Gail A
GA
D000818:Animals; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D015551:Autoimmunity / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism; D051940:B7-2 Antigen / Q000096:biosynthesis / Q000276:immunology; D019013:CD40 Antigens / Q000276:immunology; D002469:Cell Separation; D004195:Disease Models, Animal; D020031:Epstein-Barr Virus Infections / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D015850:Interleukin-6 / Q000096:biosynthesis / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000473:pathology; D008213:Lymphocyte Activation / Q000276:immunology; D008221:Lymphoid Tissue / Q000473:pathology; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D013601:T-Lymphocytes / Q000276:immunology; D014763:Viral Matrix Proteins / Q000276:immunology*
D001323:Autoantibodies; D051940:B7-2 Antigen; D019013:CD40 Antigens; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D015850:Interleukin-6; D014763:Viral Matrix Proteins
Pediatr Infect Dis J. 2001 Feb;20(2):148-53
11224832
Science. 2006 Jun 16;312(5780):1665-9
16778059
J Biol Chem. 2008 Jul 11;283(28):19255-64
18482989
J Immunol. 2007 Jan 1;178(1):271-9
17182564
Arthritis Res Ther. 2004;6(4):R295-302
15225364
J Immunol. 2005 Jun 1;174(11):6599-607
15905498
Annu Rev Immunol. 2005;23:1-21
15771564
J Clin Invest. 1997 Dec 15;100(12):3019-26
9399948
J Clin Invest. 2005 Jul;115(7):1869-78
15951839
J Immunol. 1999 Mar 1;162(5):2555-61
10072495
Nat Rev Immunol. 2009 Dec;9(12):845-57
19935804
J Immunol. 2004 Jan 15;172(2):1287-94
14707107
Nat Immunol. 2004 Mar;5(3):317-27
14758357
Clin Immunol. 2006 May;119(2):123-30
16517211
Arthritis Rheum. 2001 May;44(5):1122-6
11352244
J Exp Med. 2004 Mar 1;199(5):661-71
14981114
Curr Opin Immunol. 2006 Dec;18(6):656-64
17011767
J Immunol. 1999 Jun 1;162(11):6492-502
10352264
Nat Rev Immunol. 2004 Oct;4(10):775-86
15459669
J Exp Med. 2001 Apr 16;193(8):943-54
11304555
Immunity. 2004 Aug;21(2):255-66
15308105
J Immunol. 1999 Feb 15;162(4):2415-21
9973523
J Immunol. 1997 Jul 1;159(1):454-65
9200486
Blood. 2002 Dec 15;100(13):4557-64
12393436
J Allergy Clin Immunol. 2005 Aug;116(2):251-61; quiz 262
16083776
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6670-5
10841565
Immunity. 1994 Jun;1(3):219-29
7889410
J Immunol. 2007 Jul 15;179(2):753-63
17617564
Nat Rev Immunol. 2001 Oct;1(1):75-82
11905817
Eur J Immunol. 1999 Dec;29(12):3855-66
10601993
J Clin Invest. 1999 Jun;103(12):1685-95
10377175
J Immunol. 2005 Feb 1;174(3):1630-7
15661926
J Immunol. 1983 Oct;131(4):1797-801
6311898
Immunity. 2001 Sep;15(3):397-408
11567630
J Immunol. 1997 Jun 15;158(12):6019-28
9190957
J Immunol. 2005 Jul 15;175(2):1337-45
16002739
Immunity. 1994 Jun;1(3):167-78
7534202
Immunity. 2001 Nov;15(5):775-85
11728339
J Immunol. 2002 Sep 1;169(5):2694-700
12193743
Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17140-5
19805155
J Clin Invest. 1998 Mar 15;101(6):1362-72
9502778
Curr Opin Rheumatol. 2006 Sep;18(5):462-7
16896283
J Rheumatol. 2005 Jan;32(1):44-7
15630723